291 results
6-K
EX-99.1
PRTG
Portage Biotech Inc.
27 Aug 24
Exploration and evaluation of strategic alternatives continue
8:30am
in nature and, business strategy, plans and objectives of management for future operations and those statements preceded by, followed by or that otherwise
424B3
PRTG
Portage Biotech Inc.
27 Aug 24
Prospectus supplement
6:11am
to Reader dated August 26, 2024)
NOTE 1. NATURE OF OPERATIONS
Portage Biotech Inc. (the “Company” or “Portage”) is incorporated in the British Virgin … Interim Financial Statements
(U.S. Dollars)
(Unaudited – See Notice to Reader dated August 26, 2024)
NOTE 1. NATURE OF OPERATIONS (Cont’d)
As a result
6-K
EX-99.1
PRTG
Portage Biotech Inc.
27 Aug 24
Current report (foreign)
6:05am
to Condensed Consolidated Interim Financial Statements
(U.S. Dollars)
(Unaudited – See Notice to Reader dated August 26, 2024)
NOTE 1. NATURE … – See Notice to Reader dated August 26, 2024)
NOTE 1. NATURE OF OPERATIONS (Cont’d)
As a result of the reverse stock split, every twenty (20) pre-split
6-K
EX-99.2
PRTG
Portage Biotech Inc.
27 Aug 24
Current report (foreign)
6:05am
OF CONTENTS
Page No.
Forward-Looking Statements
Nature of Operations and Overview
Summary of Results
Number of Ordinary Shares
Business Environment … in our unaudited condensed consolidated interim financial statements for the three months ended June 30, 2024.
Nature of Operations and Overview
Due
POS AM
PRTG
Portage Biotech Inc.
22 Aug 24
Prospectus update (post-effective amendment)
6:24pm
in the BVI and given the nature of our business and assets at the current time, the ESA has little material impact on us and our operations. However
424B3
pq4p05mgn knjau
15 Aug 24
Prospectus supplement
8:31am
6-K
EX-99.1
nv4kx83zv
15 Aug 24
Current report (foreign)
8:00am
424B3
ft95s4owap
13 Aug 24
Prospectus supplement
8:52am
6-K
EX-99.1
lkjsxqyf 4nne2
13 Aug 24
Portage Biotech Announces 1-for-20 Reverse Stock Split
8:00am
424B3
7aumn2jiz ym78
12 Apr 24
Prospectus supplement
5:22pm
6-K
EX-99.1
77rwyd1c
12 Apr 24
Portage Biotech Announces Plans to Expand its Evaluation of Strategic Alternatives
5:21pm
6-K
EX-99.1
djwzcu7gy x6oj6
28 Feb 24
Company focused on adenosine platform clinical development
6:42pm
424B3
xhafsfdlltrrf
28 Feb 24
Prospectus supplement
5:19pm
6-K
EX-99.1
3fodcsjsw06b3rip
28 Feb 24
Current report (foreign)
5:17pm
6-K
EX-99.2
0aiuwl6bwq ylu2e
28 Feb 24
Current report (foreign)
5:17pm
424B3
yerpvc0 wvw8y2vkl2f4
4 Jan 24
Prospectus supplement
5:49pm
6-K
EX-99.1
6z3 dawyt
4 Jan 24
Current report (foreign)
8:10am
424B3
styedsjrj8vomp5fijs
28 Nov 23
Prospectus supplement
4:03pm